Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 91

1.

Italian multicenter survey to evaluate the opinion of patients and their reference clinicians on the "tolerance" to targeted therapies already available for non-small cell lung cancer treatment in daily clinical practice.

Novello S, Capelletto E, Cortinovis D, Tiseo M, Galetta D, Valmadre G, Casartelli C, Rapetti SG, Rossi A.

Transl Lung Cancer Res. 2014 Jun;3(3):173-80. doi: 10.3978/j.issn.2218-6751.2014.06.10.

2.

CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients.

Facchinetti F, Aldigeri R, Aloe R, Bortesi B, Ardizzoni A, Tiseo M.

Tumour Biol. 2015 Mar 3. [Epub ahead of print]

PMID:
25731731
3.

Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH.

Bordi P, Tiseo M, Buti S, Regolisti G, Ardizzoni A.

Tumori. 2015 Feb 20;0(0):0. doi: 10.5301/tj.5000249. [Epub ahead of print]

PMID:
25702667
4.

Concomitant EGFR and KRAS mutations in ALK-rearranged lung cancer.

Rossi G, Baldi L, Barbieri F, Bertolini F, Tiseo M.

Ann Oncol. 2015 Feb 10. pii: mdv067. [Epub ahead of print] No abstract available.

PMID:
25669831
5.

Different clinical effects upon separate inhibition of coexisting EGFR and PI3KCA mutations in a lung adenocarcinoma patient.

Tiseo M, Bersanelli M, Perrone F, Tamborini E, Settanni G, Busico A, Rossi G, Ardizzoni A, Pelosi G.

Lung Cancer. 2015 Feb;87(2):204-6. doi: 10.1016/j.lungcan.2014.12.008. Epub 2014 Dec 19.

PMID:
25555368
6.

Gene mutations in small-cell lung cancer (SCLC): results of a panel of 6 genes in a cohort of Italian patients.

Bordi P, Tiseo M, Barbieri F, Bavieri M, Sartori G, Marchetti A, Buttitta F, Bortesi B, Ambrosini-Spaltro A, Gnetti L, Silini EM, Ardizzoni A, Rossi G.

Lung Cancer. 2014 Dec;86(3):324-8. doi: 10.1016/j.lungcan.2014.10.002. Epub 2014 Oct 12.

PMID:
25453846
7.

Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer: treatment rationale and protocol design of the GOIRC-AIFA FARM6PMFJM trial.

Tiseo M, Boni L, Ambrosio F, Camerini A, Vitale MG, Baldini E, Cinieri S, Zanelli F, Defraia E, Passalacqua R, Crino L, Dazzi C, Tibaldi C, Turolla GM, D'Alessandro V, Zilembo N, Riccardi F, Ardizzoni A; Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).

Clin Lung Cancer. 2015 Jan;16(1):67-70. doi: 10.1016/j.cllc.2014.09.001. Epub 2014 Sep 28.

PMID:
25450879
8.

First-line chemotherapy treatment of advanced non-small-cell lung cancer: does cisplatin versus carboplatin make a difference?

Tiseo M, Ardizzoni A, Boni L.

J Thorac Oncol. 2014 Nov;9(11):e82. doi: 10.1097/JTO.0000000000000272. No abstract available.

PMID:
25436810
9.

MET and Small-Cell Lung Cancer.

Gelsomino F, Rossi G, Tiseo M.

Cancers (Basel). 2014 Oct 13;6(4):2100-15. doi: 10.3390/cancers6042100. Review.

10.

Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.

Landi L, Tiseo M, Chiari R, Ricciardi S, Rossi E, Galetta D, Novello S, Milella M, D'Incecco A, Minuti G, Tibaldi C, Salvini J, Facchinetti F, Haspinger ER, Cortinovis D, Santo A, Banna G, Catino A, GiajLevra M, Crinò L, de Marinis F, Cappuzzo F.

Clin Lung Cancer. 2014 Nov;15(6):411-417.e4. doi: 10.1016/j.cllc.2014.07.002. Epub 2014 Aug 16.

PMID:
25242668
11.

CT-guided biopsy of pulmonary nodules: is pulmonary hemorrhage a complication or an advantage?

De Filippo M, Saba L, Silva M, Zagaria R, Concari G, Nizzoli R, Bozzetti C, Tiseo M, Ardizzoni A, Lipia S, Paladini I, Macarini L, Carrafiello G, Brunese L, Rotondo A, Rossi C.

Diagn Interv Radiol. 2014 Sep-Oct;20(5):421-5. doi: 10.5152/dir.2014.14019.

12.

Prognostic role of hyponatremia in 564 small cell lung cancer patients treated with topotecan.

Tiseo M, Buti S, Boni L, Mattioni R, Ardizzoni A.

Lung Cancer. 2014 Oct;86(1):91-5. doi: 10.1016/j.lungcan.2014.07.022. Epub 2014 Aug 2.

PMID:
25130081
13.

Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series.

Chiari R, Buttitta F, Iacono D, Bennati C, Metro G, Di Lorito A, Iezzi M, Tiseo M, Mazzoni F, Cappuzzo F, Marchetti A, Crinò L.

Clin Lung Cancer. 2014 Nov;15(6):470-4. doi: 10.1016/j.cllc.2014.06.004. Epub 2014 Jun 24. No abstract available.

PMID:
25087901
14.

BOLERO-3 results: pharmacological activity or pharmacokinetic effect?

Buti S, Bersanelli M, Tiseo M, Ardizzoni A, Musolino A.

Lancet Oncol. 2014 Jul;15(8):e304. doi: 10.1016/S1470-2045(14)70242-6. No abstract available.

PMID:
24988929
15.

Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: a pooled analysis of topotecan second-line trials.

Ardizzoni A, Tiseo M, Boni L.

Eur J Cancer. 2014 Sep;50(13):2211-8. doi: 10.1016/j.ejca.2014.06.002. Epub 2014 Jun 26.

PMID:
24981975
16.

Gefitinib and afatinib treatment in an advanced non-small cell lung cancer (NSCLC) patient undergoing hemodialysis.

Bersanelli M, Tiseo M, Artioli F, Lucchi L, Ardizzoni A.

Anticancer Res. 2014 Jun;34(6):3185-8.

PMID:
24922692
17.

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.

Cretella D, Saccani F, Quaini F, Frati C, Lagrasta C, Bonelli M, Caffarra C, Cavazzoni A, Fumarola C, Galetti M, La Monica S, Ampollini L, Tiseo M, Ardizzoni A, Petronini PG, Alfieri RR.

Mol Cancer. 2014 Jun 5;13:143. doi: 10.1186/1476-4598-13-143.

18.

Overcoming T790M-driven acquired resistance to EGFR-TKIs in NSCLC with afatinib: a case report.

Bordi P, Tiseo M, Bortesi B, Naldi N, Buti S, Ardizzoni A.

Tumori. 2014 Jan-Feb;100(1):e20-3. doi: 10.1700/1430.15832.

PMID:
24675505
19.

Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC).

Tiseo M, Andreoli R, Gelsomino F, Mozzoni P, Azzoni C, Bartolotti M, Bortesi B, Goldoni M, Silini EM, De Palma G, Mutti A, Ardizzoni A.

Lung Cancer. 2014 Feb;83(2):265-71. doi: 10.1016/j.lungcan.2013.12.001. Epub 2013 Dec 12.

PMID:
24388705
20.

Fishing for ALK with immunohistochemistry may predict response to crizotinib.

Bavieri M, Tiseo M, Lantuejoul S, McLeer-Florin A, Lasagni A, Fantini R, Rossi G.

Tumori. 2013 Sep-Oct;99(5):e229-32. doi: 10.1700/1377.15321.

PMID:
24362875
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk